Dr. Reddy’s executive files initial ownership report

DR REDDYS LABORATORIES LTD executive Milan Kantilal Kalawadia, CEO – North America, has filed an initial Form 3 reporting his ownership in the company.

Accepted by SEC EDGAR 04/01/2026 - 12:42 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

DR REDDYS LABORATORIES LTD executive Milan Kantilal Kalawadia, CEO – North America, has filed an initial Form 3 reporting his ownership in the company. The filing lists 47,325 Equity Shares underlying ADRs held with direct ownership, and does not report any recent purchases or sales.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider KALAWADIA MILAN KANTILAL

Role CEO - North America

Type	Security	Shares	Price	Value
Holding	Equity Shares underlying ADRs	--	--	--

Holdings: Equity Shares underlying ADRs — 47,325 shares (Direct)

Key Figures

Directly owned shares: 47,325 Equity Shares underlying ADRs

1 metrics

Directly owned shares 47,325 Equity Shares underlying ADRs Beneficial ownership reported on Form 3

Key Terms

Form 3, Equity Shares underlying ADRs, beneficial ownership

3 terms

Form 3 regulatory

"has filed an initial Form 3 reporting his ownership"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Equity Shares underlying ADRs financial

"The filing lists 47,325 Equity Shares underlying ADRs held"

beneficial ownership financial

"represents his beneficial holdings as disclosed in the Form 3"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the DR REDDYS LABORATORIES (RDY) Form 3 filing show?

The Form 3 shows an initial ownership report by Milan Kantilal Kalawadia, CEO – North America. It discloses direct ownership of 47,325 Equity Shares underlying ADRs, establishing his baseline stake without indicating any recent share purchases or sales.

How many DR REDDYS LABORATORIES (RDY) shares does Milan Kantilal Kalawadia report?

Milan Kantilal Kalawadia reports direct ownership of 47,325 Equity Shares underlying ADRs. This figure represents his beneficial holdings as disclosed in the Form 3 and serves as the starting point for tracking any future insider transactions in DR REDDYS LABORATORIES.

Is the RDY Form 3 a buy or sell transaction?

The RDY Form 3 is not a buy or sell transaction. It is an initial ownership statement listing 47,325 Equity Shares underlying ADRs held directly by Milan Kantilal Kalawadia, providing a baseline for his stake rather than reporting new trading activity.

Who is the insider in the DR REDDYS LABORATORIES (RDY) Form 3 filing?

The insider is Milan Kantilal Kalawadia, who serves as CEO – North America for DR REDDYS LABORATORIES. The Form 3 records his direct ownership of 47,325 Equity Shares underlying ADRs, giving investors visibility into his reported equity position with the company.

What does “Equity Shares underlying ADRs” mean for RDY?

“Equity Shares underlying ADRs” refers to the company’s ordinary equity shares that back its American Depositary Receipts. The Form 3 states that Milan Kantilal Kalawadia holds 47,325 of these underlying shares directly, reflecting his economic interest related to RDY’s ADRs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

KALAWADIA MILAN KANTILAL

(Last) (First) (Middle)

36 MOUNT DRIVE

(Street)

NORTH BRUNSWICK NEW JERSEY 08902

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
12/18/2025

3. Issuer Name and Ticker or Trading Symbol
DR REDDYS LABORATORIES LTD [ RDY ]

3a. Foreign Trading Symbol
[DRREDDY&500124]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO - North America

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Equity Shares underlying ADRs	47,325	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ KALAWADIA MILAN KANTILAL	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)